<aside> 📺

Watch this 9 min video chapter to master the powerful Startup or Company evaluation workflows - with multiple ways to assess Technologies, Drug Research, Preclinical work, In-Licensing Opportunities, or any questions you’d like to ask.

https://share.descript.com/view/Tec5VnCq7Fo?t=1106

</aside>

<aside> 1️⃣

Optional: Start from your company’s interests:

Example: Go to Pfizer profile and Ask Anything:

<aside> ❓

Based on what you have on Pfizer's developments wrt novel multispecifics, how would you summarize the (external) innovation interests on multispecifics? The goal is to use this information to compare any new technology with to see how well it may fit Pfizer's interest

</aside>

• AI Answer: (click to open) </aside>

<aside> 2️⃣

In a new tab: Query in Companies:

<aside> 🔎

"multi-specific" OR bispecific OR "bi-specific" OR trispecific OR "tri-specific”

</aside>

</aside>

<aside> 3️⃣

Visit a profile - AI Evaluation

<aside> ✨

1. Summary
2. Technology
3. Preclinical Activities
4. Drug Research
5. In-licensing Opportunity (use Pfizer interests info, for example) </aside>

</aside>

<aside> 4️⃣

Filter companies:

<aside> ✅

Preclinical therapeutic startups

</aside>

</aside>

<aside> 5️⃣

All results: AI →In-Licensing Opportunity

What types of assets or IP are you scouting for?

<aside> ❓

bispecifics, trispecifics or multispecifics. See context on our interests:

Pfizer's recent research and development efforts underscore a robust and evolving interest in multispecific modalities, particularly multispecific antibodies—including bispecific and trispecifics—aimed at both hematological malignancies and solid tumors. Externally, the innovation focus can be summarized in three main areas: T cell–engaging multispecifics (including BiTEs and bispecific antibodies), multispecific immune co-stimulatory agonists, and next-generation bioprocessing and manufacturing strategies.

1. Oncology and Hematology: Multispecifics and T cell Engagers

• Pfizer is deeply engaged in developing and optimizing bispecific antibodies for cancer, most notably with elranatamab, a BCMA-CD3 bispecific antibody for multiple myeloma. Recent publications indicate the use of advanced quantitative systems pharmacology approaches to optimize dosing regimens, signifying a data-driven commitment to the clinical success of these agents[Source].
• In solid tumors, Pfizer is advancing novel T cell engagers such as PF-07260437, a B7-H4xCD3 bispecific for breast cancer, with demonstrated preclinical efficacy and combinatorial potential with checkpoint inhibitors and standard therapies[Source].
• Another focus is on conditionally active co-stimulatory bispecifics, such as CD228-4-1BB (PF-08046049), which are designed for synergistic use with checkpoint inhibitors to enhance anti-tumor immunity while minimizing systemic toxicity, a strategy that parallels advances in CAR-T and other cellular therapies[Source].

2. Multispecific Platform and Manufacturing Innovations

• Pfizer is investing in new bioprocessing strategies to make multispecific antibody production more reliable and scalable. Two-part work from 2025 demonstrates a focus on coculturing and column-based redox reactions for efficient, high-yield heterodimer (multispecific) antibody production, addressing complexity and impurity challenges on the manufacturing side[Source][Source].

3. Pipeline and Clinical Application Focus

• Pfizer's multispecific programs—the clinical, preclinical, and IP—are notably concentrated in immuno-oncology and hematology. The patent landscape further supports this, with filings for mono- and bispecifics targeting EGFRvIII, BCMA, and B7-H4 for oncology applications in both hematologic (e.g., multiple myeloma) and solid tumors[Source][Source]. Clinical trial and publication activity is largely focused around elranatamab for multiple myeloma, highlighting real-world deployment and optimization of bispecifics as a therapeutic class.

4. Strategic Themes in External Innovation

• Pfizer's scientific communications and clinical trial activity reveal keen interest in 1) expanding the mechanistic diversity of multispecific therapeutics (e.g., targeting new tumor-specific antigens for solid tumors), 2) optimizing combinations of multispecifics with other immunotherapeutic agents (checkpoint inhibitors, SOC, etc.), and 3) overcoming limitations of earlier T cell engagers (toxicity, target specificity, manufacturing complexity).
• Additionally, significant attention is paid to health equity and access barriers to bispecifics and cell therapies, suggesting commercial and external collaboration opportunities to close these gaps[Source].

Summary for Fit Assessment

If you are evaluating a new multispecific technology for Pfizer, the optimal fit will be with:

• Platforms addressing immune cell engagement (especially T cells) or novel tumor antigens, particularly in difficult-to-treat cancers (e.g., breast, multiple myeloma, IO-resistant solid tumors).
• Technologies offering improved manufacturability, purity, or scalable processes for complex multispecifics.
• Approaches that can be positioned within combination regimens or address prior toxicities or accessibility challenges with existing modalities.

Pfizer’s external innovation interests remain firmly rooted in advancing the clinical, technical, and commercial boundaries of multispecific antibodies, with a focus on efficient production, real-world applicability, combination potential, and equity of patient access.

</aside>

</aside>

<aside> 6️⃣

Company In-Licensing Evaluation Report

<aside> ➡️

• See Report here: (click to open) </aside>

</aside>

<aside> 7️⃣

Detailed In-Licensing Evaluation per Company in Excel

<aside> ➡️

Access the Excel file analysis here:

In-Licensing Opportunities.xlsx

</aside>

</aside>